Research institute partners with universities to license life science tech

The Indiana Bioscience Research Institute (IBRI) ,a non-profit research organisation, has partnered with four Indiana-based universities to license life sciences technologies.

Indiana University, Ball State University, Purdue University and the University of Notre Dame are the four partner universities.

The agreement will provide IBRI with quicker access to available technologies that can be pooled with its own research to help commercialise technologies at a quicker rate.

According to IBRI, the agreement accelerates the process for the licensing of university technology, as well as removing obstacles to acquire technologies.

Some of the first technologies to be licensed include a mass spectrometry technology and a high sensitivity detection technology for single cell analysis developed at Purdue.

The University of Notre Dame will license a microfluidic technology.

Indiana University’s School of Medicine is already working closely with IBRI as researchers. The two are working together to advance investigation in areas linked to cardio metabolic disease.

Rainer Fischer, chief scientific and innovation officer at IBRI, said: “With this arrangement in place, the IBRI will be able to unlock the value of discoveries being made at the state’s top research universities by further developing them or combining them with other technologies and bringing treatments to patients and innovations quicker to market.”

Bryan Ritchie, vice president of innovation at the University of Notre Dame, added: “Not only will IBRI work to make new discoveries in the biosciences arena, but it will facilitate the collaboration and engagement of all the major bioscience players in Indiana.”

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.

Sign up for our latest webinar, Biotech patentability issues in Europe.